Pulse Medical Imaging Technology Completes Strategic Financing

Pulse Medical Imaging Technology (Shanghai) Co., Ltd completed the B round of hundreds of millions of yuan in strategic financing. Shanghai STVC Group made a strategic capital injection, Hillhouse Ventures led the investment, and the original shareholder Bohang Capital followed the investment.

The founding team of Pulse has been deeply involved in the field of coronary imaging and computational coronary function for many years, and invented the world's first new method for fast calculation of FFR based on coronary angiography, namely Quantitative Blood Flow Fraction (QFR), and successfully developed it in China and Europe. The hospital carried out clinical use. QFR products based on coronary angiography entered the China National Food and Drug Administration Special Approval for Innovative Medical Devices in 2017, and obtained the NMPA Class III Medical Device Registration Certificate in July 2018.

Pulse has built a full-imaging FFR product line from coronary heart disease screening to precise intraoperative diagnosis, from coronary CTA-based, coronary angiography, and intracavitary imaging. In the future diagnosis and treatment of coronary heart disease, when a patient undergoes any coronary imaging examination, he can obtain the diagnosis result of coronary artery function immediately, so as to realize accurate patient triage and formulate precise treatment strategy. Calculating coronary artery function will become a routine diagnostic method for patients with coronary heart disease, rather than a diagnostic method that requires additional complicated operations.

It is reported that Pulse will carry out technological and product innovations in the fields of cerebrovascular and peripheral blood vessels in the future, bringing more effective and economical technologies and products to more patients.

Since the establishment of the company, Pulse has undertaken or participated in 6 major national and Shanghai scientific research and industrialization projects, and actively integrated into the national strategic technological innovation system, including the first batch of key digital medical equipment research and development projects in the country’s 13th Five-Year Plan period, and the Ministry of Science and Technology "Technology Boosts Economy 2020" key special projects, major projects of Shanghai's strategic emerging industries, Shanghai "Science and Technology Innovation Action Plan", Shanghai's key international cooperation projects, etc.

Shanghai STVC Group operates as a venture capital firm. The Company invests in energy saving and environmental protection, information technology, biomedicine, high-end equipment manufacturing, new energy, and other fields. Shanghai STVC Group conducts businesses in China.